Pancreatic islet cell tumors
, also known as neuroendocrine tumors, are a rare form of the disease affecting two to four people per million worldwide annually, or about 5% of pancreatic cancer cases, according to the National Cancer Institute.
Pfizer's Phase III trial of Sutent was stopped early after the drug showed significant benefit in patients with advanced pancreatic islet cell tumors
, or pancreatic neuroendocrine tumors.
The pancreatic islet cell tumors
associated with FMEN1 tend to be numerous and small, but most are benign and do not release active hormones into the blood.
Non-islet origin of pancreatic islet cell tumors
. J Clin Endocrinol Metab.